Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP

Launched by NORTHWESTERN UNIVERSITY · Nov 11, 2022

Keywords

ClinConnect Summary

This clinical trial is studying whether the use of a medication called furosemide, given during a specific type of prostate surgery known as Holmium Laser Enucleation of the Prostate (HoLEP), can help more patients go home on the same day of their surgery. HoLEP is a treatment for benign prostatic hyperplasia (BPH), a condition that can cause urinary problems. The trial aims to see if giving furosemide, which helps the body produce urine, makes a difference in how quickly patients can be discharged after the procedure.

To be eligible for this study, participants must be men aged 18 to 89 who are planning to undergo HoLEP and can provide informed consent. However, those with known allergies to furosemide, certain severe medical conditions, or those needing other surgeries at the same time will not be included. Participants in the trial can expect to have regular assessments and questionnaires about their experience, and their results will help determine the best practices for future patients undergoing HoLEP.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Males 18 -89 undergoing HoLEP
• • Willing to sign the Informed Consent Form
• • Able to read, understand, and complete patient questionnaires.
• Exclusion Criteria:
• • Allergy or hypersensitivity to furosemide or other loop diuretic
• • Anuric patients or patients with liver failure
• • Patients having a concurrent ureteroscopy +/- laser lithotripsy, percutaneous nephrolithotomy, or non-urologic surgery at the time of their HoLEP
• • Anticipated need for perineal urethrostomy at the time of HoLEP
• • Patient not undergoing catheter removal and voiding trial at Northwestern Memorial Hospital